Critical Analysis: Curaleaf (CURLF) vs. The Competition

Curaleaf (OTCMKTS:CURLF) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare Curaleaf to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and risk.

Earnings and Valuation

This table compares Curaleaf and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Curaleaf	$1.27 billion	-$231.07 million	-234.25
Curaleaf Competitors	$1.88 billion	$139.14 million	9.47

Curaleaf’s peers have higher revenue and earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

0.0% of Curaleaf shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Curaleaf and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curaleaf	0	1	2	1	3.00
Curaleaf Competitors	4274	10549	18323	829	2.46

Curaleaf currently has a consensus price target of $6.00, suggesting a potential downside of 35.97%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.40%. Given Curaleaf’s peers higher possible upside, analysts plainly believe Curaleaf has less favorable growth aspects than its peers.

Profitability

This table compares Curaleaf and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curaleaf	-2.62%	-0.88%	-0.26%
Curaleaf Competitors	-278.24%	-150.08%	-21.87%

Risk and Volatility

Curaleaf has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Curaleaf’s peers have a beta of 2.53, suggesting that their average share price is 153% more volatile than the S&P 500.

Summary

Curaleaf peers beat Curaleaf on 8 of the 13 factors compared.

About Curaleaf

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.